肝病藥物市場：依治療方法、通路和地區分類

Liver Diseases Therapeutics Market, Therapy Type, By Distribution Channel, and By Region

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到2026年，肝病治療市場規模將達225.5億美元，2033年將達到439.4億美元。預計從2026年到2033年，該市場將以10.0%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	225.5億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.00%	2033年市場規模預測：	439.4億美元

肝臟是人體最大的器官，在消化食物、儲存能量和排放毒素方面發揮著至關重要的作用。肝臟疾病種類繁多，包括病毒性疾病，如甲型、乙型和丙型肝炎，以及藥物、毒素或過量飲酒引起的疾病，如脂肪肝和肝硬化。肝癌也是發病率不斷上升的疾病之一。此外，還有一些遺傳性疾病會影響肝臟，例如血鐵沉著症和威爾森氏症。肝臟疾病的常見症狀包括腹部和腿部腫脹、容易瘀青、黃疸以及糞便和尿液顏色改變。影像檢查和肝功能檢查可以確診肝臟損傷並診斷肝臟疾病。肝臟疾病的治療方案包括抗排斥藥物/免疫抑制劑、化療藥物、分子標靶治療、疫苗、抗病毒藥物、免疫球蛋白和皮質類固醇。

市場動態

肝病盛行率的不斷上升、新療法的研發以及肝病治療藥物的法規核准，正在成長要素。例如，2022年5月26日，美國製藥公司輝瑞宣布，其用於治療非酒精性脂肪性肝炎（NASH）合併肝纖維化的臨床實驗聯合治療已獲得美國食品藥物管理局（FDA）的簡審類。快速通道旨在加速新藥和疫苗的研發和核准，以滿足治療或預防嚴重方面尚未滿足的需求。此聯合治療使用的兩種藥物分別是艾沃加司他（elvogastat）和克立司他（cresacostat）。這項決定是基於輝瑞的非臨床和IIa期臨床試驗結果，這些試驗表明，這兩種藥物能夠減少肝臟脂肪，並證實其具有良好的安全性和耐受性。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球肝病治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球肝病治療市場」報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用全球肝病治療市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

Astellas Pharma Inc.
Bristol-Myers Squibb.
Gilead Sciences
Glaxosmithkline Plc
Hoffmann-La Roche Ltd
Merck & Co.
Novartis AG
Sanofi SA
Pfizer Inc.
Takeda Pharmaceuticals
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

第8章

調查方法
關於本公司

簡介目錄

Product Code: CMI3809

Liver Diseases Therapeutics Market is estimated to be valued at USD 22.55 Bn in 2026 and is expected to reach USD 43.94 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 22.55 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.00%	2033 Value Projection:	USD 43.94 Bn

Liver is the largest organ of the human body. It helps to digest food, store energy, and remove poisons. There are many kinds of liver diseases like diseases caused by viruses such as hepatitis A, hepatitis B, and hepatitis C. Diseases can also be caused by drugs, poisons, or too much alcohol consumption. Examples include fatty liver disease and cirrhosis. Live cancer is another growing disease. There are several inherited disorders like hemochromatosis and Wilson disease that affect the liver. The common symptoms of diseases affecting the liver include swelling of the abdomen and legs, bruising easily, Jaundice, and change in color of stool and urine. Imaging tests and liver function tests can check liver damage and diagnose liver disease. Treatments given for liver diseases include anti-rejection drugs/immunosuppressants, chemotherapy drugs, targeted therapy, vaccines, anti-viral drugs, immunoglobulins, and corticosteroids.

Market Dynamics

Increasing prevalence of liver diseases, research and development of novel therapeutics, and approvals from regulatory bodies for liver disease treatment are attributed to the growth of the global liver diseases therapeutics market. For instance, on May 26, 2022, Pfizer Inc., U.S. based pharmaceutical company announced U.S. Food and Drug Administration granted fast-track designation to Pfizer's investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of new drugs and vaccines intended to treat or prevent serious conditions and address unmet medical needs. The two drugs in combinational therapies are ervogastat and clesacostat. The decision was made based on Pfizer's nonclinical studies and phase 2a clinical study of drugs which showed reduced liver fat with favorable safety and tolerability profile.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global liver diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc..
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver diseases therapeutics market.

Detailed Segmentation:

Global Liver Diseases Therapeutics Market, Therapy Type:
Anti-Rejection Drugs/Immunosuppressant
Chemotherapy Drugs
Targeted therapy
Vaccines
Anti-Viral Drugs
Immunoglobulin's
Corticosteroids
Global Liver Diseases Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Astellas Pharma Inc. *
Bristol-Myers Squibb
Gilead Sciences
Glaxosmithkline Plc
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Sanofi S.A
Pfizer Inc.
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals, Inc.
Theratechnologies Inc.
Alnylam Pharmaceuticals, Inc.
Protagonist Therapeutics, Inc.
Dicerna Pharmaceuticals, Inc.
Endo International
Provectus Biopharmaceuticals Inc.
MAX BioPharma, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Liver Diseases Therapeutics Market, By Therapy Type, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Anti-Rejection Drugs/Immunosupressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Anti-Viral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

5. Global Liver Diseases Therapeutics Market, By Distribution Channel, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

6. Global Liver Diseases Therapeutics Market, By Region, 2021-2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021- 2033, (US$ Billion)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Glaxosmithkline Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Takeda Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Valeant Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Watson Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theratechnologies Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Alnylam Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Protagonist Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Dicerna Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Endo International
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Provectus Biopharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
MAX BioPharma, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies